Invokana Ketoacidosis, Kidney Failure and Amputation Risks Make Diabetes Drug Unreasonably Dangerous

Invokana Ketoacidosis, Kidney Failure, and Amputation Risks Make Diabetes Drug Unreasonably Dangerous.

As I sit here mulling over article strings for inclusion in my product liability blog, I am struck by a profound thought. Most normal people on New Year’s Eve make resolutions to be or become better human beings in the New Year.

I wonder what resolutions go through the collective minds of the folks at Big Pharma? Do they spend any time in regret, embarrassment or shame over the side effects of the drugs or medical devices that they have unleashed into the marketplace that creates havoc and destroys countless lives? Where are the whistle-blowers when you need them most, who know where the bodies are buried and which testing short-cuts were taken?

Or is it business as usual – as in maximizing profits at all costs in pursuit of the almighty dollar, get a bigger bonus next year, full steam ahead unburdened by conscience. I suspect, as you do, dear reader, that we know the answer to that, once more evidenced by news of increasing litigation for manufacturers’ failure.

But I digress from the topic at hand. Recently, a product liability lawsuit was filed against Johnson & Johnson’s Janssen Pharmaceuticals unit over a failure to warn about the risk of kidney failure from Invokana. According to the allegations, this lack of warning makes the infamous diabetes drug unreasonably dangerous for patients.

Jimmie Fielder filed suit in the U.S. District Court for the District of New Jersey with the claim that he would not have developed kidney failure if the manufacturers of Invokana had provided adequate warnings for diabetic patients and doctors.

Invokana Federal Multidistrict Litigation

Fielder’s case was filed in the U.S. District Court for the District of New Jersey, where more than nearly 1,000 other Invokana lawsuits are currently centralized and consolidated for coordinated pretrial proceedings, as part of a federal multidistrict litigation (MDL) before U.S. District Judge Brian Martinotti.

What is Invokana?

Invokana (canagliflozin) was approved for sale in March 2013, as the first member of a new class of diabetes drugs, known as sodium-glucose cotransporter 2 (SGLT2) inhibitors.

Similar SGLT2 drugs include Invokamet, Jardiance, Farxiga, Xigduo, and Invokana has the largest market share.

FDA Warnings over Invokana Side Effects

Since Invokana’s release, there have been many reports of catastrophic health complications from patients taking the type 2 diabetic medication. The FDA has ordered many warning label updates over the past several years.

In December 2015, the FDA ordered Johnson & Johnson to add new diabetic ketoacidosis warnings to Invokana, finding that the drug increases the risk of this dangerous medical condition.

In June 2016, the FDA ordered new label warnings about Invokana and kidney risks, finding that the drug increases the risk of acute kidney failure.

In May 2017, the FDA ordered new label warnings about Invokana and the increased risk of leg and foot amputations.

If you or someone you know developed Invokana Ketoacidosis, leg, foot, toes amputations or kidney failure by taking Invokana for the treatment of their type 2 diabetes, please call us for further information at 888-210-9693. Dr. Shezad Malik Law Firm based in Dallas, Texas is investigating Invokana Ketoacidosis, leg amputations, and kidney failure cases nationwide from folks taking Invokana for the treatment of their type 2 diabetes.